The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 339:847-848 September 17, 1998 Number 12
NextNext

Butyrolactone-Induced Central Nervous System Depression after Ingestion of RenewTrient, a "Dietary Supplement"

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Ingestion of {gamma}-hydroxybutyric acid, marketed as a "body-building supplement," may result in coma and apnea. Its sale has recently been banned by the Food and Drug Administration (FDA), but similar alternative products continue to be marketed. After the addition of water and sodium hydroxide, {gamma}-butyrolactone, a solvent, is converted to {gamma}-hydroxybutyric acid. Studies suggest that {gamma}-butyrolactone poisoning can produce a clinical picture similar to that associated with {gamma}-hydroxybutyric acid.1

RenewTrient, described on the label as a dietary supplement that "stimulates the body's own natural production of Growth Hormone," contains {gamma}-butyrolactone. We report a case of central nervous . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.